Skip to main content

Table 3 Multivariate analyses of prognostic factors based on Cox regression model

From: The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma

Outcomes Variables in the final model HR (95% CI) P*
OS Interval (>  30 vs. ≤ 30 days) 2.44 (1.48–4.01) < 0.001
N category (N2–3 vs. N0–1) 2.13 (1.44–3.16) < 0.001
CCI (≥ 1 vs. 0) 2.21 (1.38–3.54) 0.001
Age (continuous) 1.02 (1.00–1.04) 0.042
lnDNA (continuous) 1.04 (0.98–1.10) 0.173
T category (T3–4 vs. T1–2) 1.42 (0.85–2.36) 0.183
DFS Interval (> 30 vs. ≤ 30 days) 1.99 (1.27–3.11) 0.003
CCI (≥ 1 vs. 0) 1.87 (1.26–2.79) 0.002
N category (N2–3 vs. N0–1) 1.58 (1.14–2.18) 0.006
lnDNA (continuous) 1.06 (1.01–1.10) 0.018
Age (continuous) 1.01 (1.00–1.03) 0.126
DMFS Interval (> 30 vs. ≤ 30 days) 2.62 (1.54–4.47) < 0.001
N category (N2–3 vs. N0–1) 3.03 (1.93–4.77) < 0.001
lnDNA (continuous) 1.12 (1.04–1.20) 0.002
CCI (≥ 1 vs. 0) 1.50 (0.84–2.66) 0.171
LRFS Interval (> 30 vs. ≤ 30 days) 1.53 (0.76–3.08) 0.238
WHO pathology (III vs. I/II) 0.42 (0.20–0.89) 0.023
N category (N2–3 vs. N0–1) 0.63 (0.37–1.07) 0.086
lnDNA (continuous) 1.06 (0.99–1.13) 0.099
  1. Covariates including: age (continuous), gender (female vs. male), CCI score (≥ 1 vs. 0), T category (T3–4 vs. T1–2), N category (N2–3 vs. N0–1), lnDNA (continuous), WHO pathology type (III vs. I/II), IC cycles (> 2 vs. ≤ 2), concurrent chemotherapy (yes vs. no)
  2. Abbreviations: OS Overall survival, DFS Disease-free survival, DMFS Distant metastasis-free survival, LRFS Locoregional recurrence-free survival, IC Induction chemotherapy, CCI Charlson comorbidity index, HR Hazard ratio, CI Confidence interval
  3. *Wald chi-square test